LEADER 00940nam--2200349---450-
001 990001362420203316
005 20050805091849.0
035   $a000136242
035   $aUSA01000136242
035   $a(ALEPH)000136242USA01
035   $a000136242
100   $a20040122d19661948km-y0itay0103----ba
101 0 $aeng
102   $aGB
105   $a||||||||001yy
200 1 $aHerzog$fSaul Bellow
210   $aLondon$cEd. Weidenfeld and Nicolson$d1966
215   $a146 p.$d21 cm.
410  0$12001
454  1$12001
461  1$1001-------$12001
700  1$aBELLOW,$bSaul$0131293
801  0$aIT$bsalbc$gISBD
912   $a990001362420203316
951   $aVII.4.A. 383(II i (am) F.2)$b22054 L.M.$cII i (am)
959   $aBK
969   $aUMA
979   $aSIAV3$b10$c20040122$lUSA01$h1310
979   $aPATRY$b90$c20040406$lUSA01$h1736
979   $aCOPAT3$b90$c20050805$lUSA01$h0918
996   $aHerzog$917520
997   $aUNISA

LEADER 00844nam0-2200265 --450 
001 9910473256003321
005 20210607122140.0
010   $a9780367473280
100   $a20210607d2021----kmuy0itay5050----ba
101 0 $aeng
200 1 $aSynthetic peptide vaccine models$edesign, synthesis, purification, and characterization$fedited by U?sku?dar University Assoc. Prof. Mesut Karahan
210  1$aBoca Raton :$cCRC Press,$d2021
215   $axix, 292 p.$d24 cm
610 0 $aVaccini sintetici
610 0 $aVaccini sub-unità
610 0 $aImmunologia
676   $a615.372
702  1$aKarahan,$bMesut$f<1977- >
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a9910473256003321
952   $a80 293/XIV D 53$bBFA293/2021$fFFABC
959   $aFFABC
996   $aSynthetic peptide vaccine models$91806617
997   $aUNINA